Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (Clinical trial IMMerge)
2020
Abstract
Risankizumab and secukinumab are indicated for the treatment of adults with moderate-to severe plaque psoriasis and target respectively IL-23 and IL-17. To date, risankizumab and secukinumab have not been directly compared.
IMMerge directly compared the safety and efficacy of risankizumab and secukinumab in patients with moderate-to-severe plaque psoriasis using PASI 90 at weeks 16 (noninferiority) and 52 (superiority) as primary end points. Efficacy of risankizumab was noninferior to secukinumab at week 16 and superior to secukinumab at week 52 of treatment based on primary end point analyses.
Both medications had a similar safety profile.